Aims: Anaplastic thyroid cancer(ATC) is one of the most aggressive solid tumors. Mutations in the p53 gene are common in anaplastic thyroid cancer, but the effects of p53 mutations are yet to be elucidated. Here, we investigated the role of p53 in ATC. Methods: p53 mutation was detect by immunohistochemistry in ATC tissues. Expression of NIS were measured using immunohistochemistry, qRT-PCR, western blot, immunofluorescence in ATC tissues and cell line 8505c. Luciferase reporter assay was performed to examine the effect of wild-type p53 on NIS. Radioiodide uptake assay and flow cytometry analysis were used to detect the role of wild-type p53 on radioiodide uptake.and cell apoptosis in ATC cell line. Results: We showed that the p53 mutation can be detected in ATC tissues. Furthermore, we demonstrated that wild-type p53 transactivated the NIS promoter. In 8505c cells transfected with wild-type p53, treatment with radioiodine resulted in increased radioiodine uptake and increased apoptotic cell death compared with 8505c cells harboring the p53 mutation. Conclusion: In summary, transfection with wild-type p53 can increase the therapeutic effect of radioiodine by regulating the expression of the NIS.
Introduction
Anaplastic thyroid cancer (ATC) is a rare subtype of thyroid cancer [1] but accounts for a significant proportion of thyroid cancer-related deaths, being one of the most lethal human neoplasms [2, 3] . The lethality of ATC largely results from its resistance to I), also known as radioiodine, treatment is one of the most effective methods for diagnosing and treating metastatic well-differentiated thyroid cancer. Because of the carcinogenicity of its beta radiation, the purely gamma-emitting radioiodine iodine-123 or the longer half-lived iodine-125 are now more frequently used for thyroid-related diagnostic and therapeutic applications. However, studies have shown that ATC and other poorly differentiated tumors have an impaired ability to concentrate radioiodine [4] . The loss of iodine uptake capacity results largely from reduced expression of the sodium/iodide symporter (NIS), a glycoprotein expressed on the plasma membrane that mediates iodide uptake in thyrocytes and is essential for the biosynthesis of the thyroid hormones thyroxine and triiodothyronine [5] . In non-thyroid tumors, in which NIS expression is generally low, the NIS is predominantly expressed in the cytoplasm. However, in thyroid tumors, shuttling of the NIS occurs between the cytoplasm and the plasma membrane [6] . NIS expression is driven by several thyroid specific transcription factors, such as Pax8 [7, 8] , and nonspecific regulators, such as Nkx2.5 [9] . Furthermore, translocation of the NIS to the plasma membrane is also driven by several regulatory factors [10] . A recent study reported that transforming growth factor-β1, a potent inhibitor of NIS transcription in normal thyroid cells, is upregulated by FoxP3 in thyroid cancer cells [11] . Regulation of the NIS is therefore complex and suppression of NIS expression during carcinogenesis is potentially mediated by multiple mechanisms.
The tumor suppressor p53 plays a vital role in genome stability and p53 activation is a primary mechanism underlying pathological responses to DNA damaging agents such as chemotherapy and radiotherapy [12, 13] . The proteins encoded by the TP53 gene bind to DNA, regulating gene expression and preventing genome mutation. Mutations within this gene therefore increase the likelihood of uncontrolled cell division. This is exemplified by the finding that more than 50 percent of human tumors contain a mutation or deletion of the TP53 gene [14, 15] , and mutations in the p53 gene are a feature of poorly differentiated or undifferentiated thyroid carcinomas [16] [17] [18] [19] [20] [21] .
In this study, we compared ATC tissue specimens and an ATC cell line (8505c) with normal thyroid tissue and cells in terms of the frequency of p53 mutations and the expression of the NIS. 8505c cells are a widely used cell line that represent poorly differentiated thyroid tumors, displaying an impaired ability to concentrate radioiodine. Iodide uptake is a fundamental requisite for a radioiodine-based therapeutic approach to treat thyroid cancer. The relationship between p53 and the NIS was investigated in 8505c cells by transfection with wild-type p53 and the therapeutic effects of radioiodine were analyzed. By recovering the ability of thyroid cancer cells to concentrate radioiodine, the aim is to achieve effective radioiodine therapy of otherwise refractory tumors.
Materials and Methods
Tissue specimens and cell culture In total, 51 anaplastic (undifferentiated) thyroid cancer tissue specimens and 47 normal thyroid tissue specimens were obtained from Chinese patients at Shanghai Tenth People's Hospital between 2012 and 2015. All human specimens were approved by the Research Ethics Committee of Shanghai Tenth People's Hospital (Shanghai, China).
The normal thyroid cell line FRTL-5 and the p53-mutated ATC cell line 8505c were used in this study . Both cell lines were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum at 37°C in a humidified atmosphere with 5% CO 2 . Unless otherwise indicated, the TSH concentration was 1 mU/ml.
Cell line authentication
Total genomic DNA was extracted from all cell lines using a DNeasy Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's protocols. The AmpFℓSTR® COfiler® PCR Amplification kit (Applied Biosystems, Foster City, CA, USA) was used for short tandem repeat (STR) profiling. PCR amplification was performed on a GeneAmp 9700 or Veriti thermal cycler (Applied Biosystems). The PCR products were 
Immunohistochemistry (IHC)
Mutant p53 proteins have a longer half-life than wild-type p53 and therefore accumulate in the nucleus and can be detected by IHC [22] . The p53 mutation was detected by IHC using the SP kit (Thermo Fisher Scientific, Rockford, IL, USA) and a p53 monoclonal antibody (1:50; DAKO, Glostrup, Denmark). PBS was used as a negative control. The results were evaluated independently by three observers using a BH-2 optical microscope (Olympus Corporation, Tokyo, Japan) at 400× magnification. One hundred cells in each of 10 random visual fields were evaluated per slide and p53 was considered positive when more than 10% of the tumor cell nuclei showed strong staining (dark brown), as described previously [23] .
RNA extraction, reverse transcription and real-time PCR
Total RNA was extracted using TRIzol reagent (TaKaRa Bio, Shiga, Japan). cDNA was synthesized using a cDNA synthesis kit according to the manufacturer's instructions (Toyobo, Osaka, Japan), and quantified by real-time PCR on an ABI 7500 FAST system (Applied Biosystems). The reaction mix was set up using the KOD SYBR Green qPCR kit (Toyobo) and primers: NIS, 5ʹ-GCGTGGCTCTCTCAGTCAA-3ʹ (F) and 5ʹ-GCGTCCATTCCTGAGCTG-3ʹ (R), GAPDH, 5'-ACCACAGTCCATGCCATC AC-3'(F), and 5'-TCCACCACCCTGTTGCTGTA-3'(R), were obtained from Sangon Biotech (Shanghai, China). Cycling conditions were as follows: 98°C for 2 min, followed by 40 cycles of 98°C for 10 s, 60°C for 10 s, and 68°C for 30 s. Relative expression was measured in triplicate and normalized to GAPDH. Data were analyzed using the 2 −ΔΔCT method [24] . All primer sequences were validated for amplification efficiency by comparison with a genomic DNA standard curve and amplified single targets as determined by melting curve analysis. the amplification efficiency of the primers used to study NIS and GAPDH expression are 0.927 and 0.952.
Western blot analysis
Total and plasma membrane proteins were extracted using a protein extraction kit (BestBio, Shanghai, China), according to the manufacturer's instructions. Western blotting was performed using standard protocols and anti-NIS antibody (1:100; ab101084, Abcam), anti-β-actin antibody (ab8226, Abcam), antiBax antibody (ab77566, Abcam), anti-caspase-3 antibody (ab13847, Abcam), anti-bcl-2 antibody (ab692, Abcam), After incubation with the secondary antibody, immune complexes were detected using an eECL western blot kit (Thermo Fisher Scientific).
Cell transfection and luciferase promoter reporter assay [25] Cell transfections with the indicated luciferase reporter, expression vectors encoding wild-type p53 or NIS and Renilla luciferase pRL null vector were performed using TransIT-TKO and TransIT-LT1 reagents from Mirus (Mirus Bio LLC, Madison, WI, USA). Cells were transiently transfected with either the wild-type p53-containing expression vector or the Renilla luciferase pRL null vector (pRL-CMV; Promega, Madison, WI, USA), used to correct for transfection efficiency. After 48h, cell lysates were assayed for luciferase activity using the dual-luciferase assay system (Promega, Fitchburg, WI, USA).
Immunofluorescence
After using STR profiling to confirm that our cell line were of ATC origin (Table 1) , immunofluorescence analysis was preformed according to a previously published method [26] . Briefly, the tissue or cells were fixed in 4% paraformaldehyde in PBS for 10 min, and then incubated with blocking buffer (PBS 1× + BSA 1%) for 15 min after three 5-min washes in PBS. Immunostaining was performed using a rabbit polyclonal anti h-NIS antibody (1:600 dilution) [27] for 1 h. After three 5-min washes in PBS, the cells were incubated with secondary antibody conjugated with FITC (1:160 dilution; Sigma-Aldrich, St. Louis, MO, USA) for 30 min, rewashed in PBS and incubated with Hoechst for 3 min. After three final PBS washes, the cells were mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) and analyzed by fluorescent microscopy at a magnification of 400×.
I was measured as previously described [28] . Briefly, cells were seeded into 12-well plates and the culture medium was aspirated. The cells were then washed with 1 ml of Hank's balanced salt solution (Life Technologies, Gaithersberg, MD, USA) supplemented with HEPES 10 mM, pH 7.3. To initiate 125 I uptake, 500 μl of buffered HBSS containing 0.1 μCi carrier-free Na 125 I and 10 mM NaI was added to each well to obtain a specific activity of 20 mCi/mmol.
Apoptosis Flow Cytometry Analysis
Annexin V-FITC and propidium iodide flow cytometry using ApoAlert Annexin V kit (Clontech, Mountain View, CA) were used to assess the effects of cell apoptosis. Cells were harvested and stained with Annexin V-FITC and propidium iodide according to the manufacturer's protocol. Cell samples were analyzed on a FACSCalibur and apoptotic fractions were determined.
Statistical analysis
Data are expressed as the mean ± SD of values obtained from at least three independent experiments. Statistical analysis was performed using t-test and the one-factor ANOVA. P <0.05 were considered statistically significant.
Results

Increased detection of the p53 mutation and decreased NIS expression in ATC tissue and cells
To detect the p53 mutation in ATC tissue, IHC was performed using an anti-p53 monoclonal antibody. According to a previously published method [23] , one hundred cells in each of 10 random visual fields were evaluated per slide and p53 was considered positive when more than 10% of the tumor cell nuclei showed strong staining (dark brown) (Fig. 1A) . In total, 56.86% (29/51) of the ATC tissue specimens were positive for the p53 mutation, compared with 4.26% (2/47) of the normal thyroid tissue specimens. IHC staining using an NIS monoclonal antibody [29] showed a significant reduced NIS protein level in the ATC Fig. 1 (Fig. 1A) . The NIS mRNA and protein expression levels, determined by qRT-PCR and western blot analysis, respectively, were both downregulated in positive p53 mutation ATC tissue compared with normal thyroid tissue and negative p53 mutation ATC tissue (p<0.01; Fig. 1B, C) . Similar result concerning NIS mRNA and protein expression levels was found in a p53-mutated ATC cell line (8505c) compared with normal thyroid cells FRTL-5 (p<0.01, Fig. 2A and B, respectively). Immunofluorescence analysis indicated that both total NIS protein and membrane-expressed NIS protein were significantly downregulated in 8505c cells compared with normal thyroid cells (Fig. 2C) . Taken together, these findings indicate that detection of the p53 mutation is increased and NIS expression is decreased in ATC tissue and cells.
Wild-type p53 induces NIS expression in ATC cells
After using STR profiling to confirm that our cell lines were of ATC origin (Table 1) , we investigated the relationship between NIS and p53. 8505c cells were transfected with a wildtype-p53 expression vector or control vector followed by qRT-PCR and western blot analysis. The mRNA and protein expression levels of NIS were significantly increased in wild-type p53 transfected 8505c cells (p<0.01; Fig. 3A and B, respectively) . To investigate the relationship between NIS expression and the p53 mutation further, immunofluorescence analysis was performed to detect the expression of NIS in 8505c transfectants. As shown in Fig. 3C , both total NIS protein and membrane-expressed NIS protein were significantly upregulated in 8505c cells transfected with wild-type p53.
Previous studies have shown that NIS expression is regulated by several transcription regulators [30] , we examined whether wild-type p53 upregulates NIS expression through binding to NIS promoter in ATC cells. The ability of wild-type p53 to regulate NIS promoter activity was investigated by a luciferase promoter reporter assay. Luciferase activity was significantly increased when 8505c cells were co-transfected with the wild-type p53 
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Cellular Physiology and Biochemistry expression plasmid and the NIS promoter luciferase reporter plasmid (Fig. 3D) . Taken together, these findings confirmed that wild-type p53 transactivates the promoter of NIS.
I treatment induced apoptosis in normal thyroid FRTL-5 cells and anaplastic thyroid 8505c cancer cells
To investigate whether decreased expression of NIS correlates with impaired iodine uptake in thyroid cells, cells were treated with 125 I and the uptake of radioiodine was assessed. Radioiodine uptake was found to be significantly reduced in 8505c cells compared with FRTL-5 cells (p<0.01; Fig. 4A) . Next, the effect of radioiodine on cell apoptosis was investigated by flow cytometry.
125
I was found to induce apoptosis in both cell types (Fig.  4B) . However, the percentage of apoptosis was significantly reduced in 8505c cells (34.1%) treated with (Fig. 4C, D) . The expression of pro-apoptotic proteins Bax and caspase-3 was decreased, whereas the expression of anti-apoptotic protein Bcl-2 was increased in Transfection with wild-type p53 rescues radioiodine uptake and promotes apoptosis in ATC cells treated with 125 I To investigate whether wild-type p53 improves radioiodine uptake and promotes apoptosis in ATC cells treated with 125 I, 8505c cells were transfected with wild-type-p53 or control vector were analyzed. Radioiodine uptake was significantly increased in 8505c cells transfected with wild-type p53 (Fig. 5A) . Furthermore, 125 I treatment induced cell apoptosis (Fig. 5C, D) . Taken together, these findings indicate that wild-type p53 transfection restores radioiodine uptake and promotes apoptosis in ATC cells treated with 125 I, a promising result in terms of anti-cancer therapy.
Discussion
The NIS-mediated ability of thyroid cancer cells to concentrate iodide is exploited for the purposes of diagnostic imaging and radioiodine therapy [31, 32] . However, ATC, a rare subtype of poorly differentiated thyroid tumor, is refractory to radioiodine therapy. The loss of iodine uptake capacity in non-differentiated cancers results from suppression of NIS expression [4] . By contrast, NIS expression has been found to be upregulated in a range of cancers including breast and liver. In these non-thyroid cancers, NIS is retained intracellularly and in some cases is reported to play a role in cell migration and invasion during carcinogenesis rather than iodide uptake [33] [34] [35] [36] . Previous studies have shown that defects in NIS function usually occur at the gene expression level [6] . Various factors have been identified to be involved in the transcriptional regulation of NIS expression. In thyroid cancers, NIS expression is mainly controlled by the transcription factors Pax-8 and Nkx2.1, which target the upstream enhancer (NUE), and by the cardiac homeobox transcription factor Nkx2.5, which regulates the activity of the NIS core promoter [9, [37] [38] [39] . Recently, in liver cancer cells, p53 was shown to mediate transcriptional activation of the NIS in response to DNA damage, triggering DNA damage-induced apoptosis [30] . Previous studies have shown that a higher frequency of mutations in p53 in ATC [40] and p53 plays an important role in developing ATC [41] . A correlation between p53 suppression, a lack of differentiation markers including NIS, and poor patient prognosis has previously been noted [19, 42] , however, studies confirming that NIS is a target gene for p53-family members in thyroid cancer cells was lacking.
Here, we present evidence that 8505c cells transfection with wild-type p53 transactivates the NIS promoter, increasing endogenous NIS expression and targeting this glycoprotein to the plasma membrane. Accumulation of NIS in wild-type p53-transfected cells resulted in increased radioiodine uptake and increased cell apoptosis following treatment with 125 I. The role of NIS accumulation in cell apoptosis was confirmed previous findings [30] . The regulation of the NIS by p53 indicates the potential therapeutic benefit in restoring the radioiodine uptake ability of poorly differentiated thyroid cancer cells. Further studies are now required to determine whether p53 alone or in combination with other regulatory factors could be employed to enhance radioiodine uptake by thyrocytes, potentially increasing the responsiveness of patients with ATC to radioiodine therapy.
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